LYEL Live signals | Maximize Profits with Getagraph.com

SELL 88736 min ago

@ $1.790

Issued: 14 Feb 2024 @ 09:30

Return: 34.08%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 1.71 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

Stats
Today's Volume	1.99M
Average Volume	913 182
Market Cap	609.83M
EPS	$0 ( 2024-02-27 )
Next earnings date	( $-0.200 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.58
ATR14	$0.0110 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-09	Lang Matthew	Buy	500 000	Option (right to buy)
2024-02-09	Lang Matthew	Buy	50 000	Common Stock
2024-02-09	Hill Stephen J.	Buy	400 000	Stock Option (right to buy)
2024-02-09	Hill Stephen J.	Buy	40 000	Common Stock
2024-02-09	Lee Gary K.	Buy	400 000	Stock Option (right to buy)

INSIDER POWER
40.01
Last 94 transactions
Buy: 113 687 542 \| Sell: 91 558 207

Volume Correlation

Long: -0.15 (neutral)

Short: -0.97 (very strong negative)

Signal:(42.968) Neutral

Lyell Immunopharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lyell Immunopharma, Inc. Correlation - Currency/Commodity

-0.30
( neutral )

-0.38
( neutral )

0.00
( neutral )

-0.02
( neutral )

0.00
( neutral )

0.43
( neutral )

Lyell Immunopharma, Inc. Financials

Annual	2023
Revenue:	$130 000
Gross Profit:	$-20.12M (-15 476.92 %)
EPS:	$-0.930

Q4	2023
Revenue:	$13 000.00
Gross Profit:	$-5.04M (-38 800.00 %)
EPS:	$-0.210

Q3	2023
Revenue:	$25 000.00
Gross Profit:	$-5.08M (-20 316.00 %)
EPS:	$-0.200

Q2	2023
Revenue:	$27 000.00
Gross Profit:	$-4.51M (-16 711.11 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.